Invest in establishing effective pre-treatment evaluation and during treatment assessment support for patients as part of CSR initiative.Show Interest
Invest in supporting Drug Resistant TB management. Program is adopting new solutions to treat DR-TB, support in rollout of new approaches in diagnosis and treatment of DR-TB as per the new guidelines of the program.
Resistance to anti-TB drugs can occur when these drugs are misused or mismanaged. Examples include when patients do not complete their full course of treatment; when there is wrong drug combination, the wrong dose, or length of time for taking the drugs ; when the supply of drugs is not always available; or when the drugs are of poor quality.
High cost and limited availability of proper medication is a challenge in managing and treating DR-TB. Often, patients experience adverse effects from the drugs and tend to interrupt their treatment, which further decrease their chances of favorable outcome.
In some cases, extensively drug-resistant TB (XDR-TB) may develop with additional resistance to more anti- TB drugs, and this responds to even fewer available medicines.
In order to prevent these challenges, it is best to control drug-resistant TB by:
Corporate sector with its reach among workers, communities along with expertise and resources can play a vital role in fulfilling the vision of a TB Free India. Corporates can facilitate early diagnosis and treatment of TB cases in the community which is an important step in TB elimination. These help in mitigating the risks of transmission of disease to others, poor health outcomes; and social and economic hardships of the patient and their family.
Despite TB being a curable disease and free of cost treatment being provided by the Government, India continues to have the highest incidence of TB in the world along with highest TB mortality. Prime Minister Mr Narendra Modi committed to eliminate TB in India by 2025. It is an ambitious target and there is a need for increased investments and partnerships by all sectors including the corporate sector to contribute to the goal of making India TB free. These partnerships will not only save lives but also help your brand gain the visibility it deserves as it cares for its people and communities, and support interventions with measurable outcomes.
Delay in accurate diagnosis of tuberculosis in India is also due to untrained first line of contact, be it allopaths or alternative medicine.